Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM

Abroad (travel likely)RecruitingPHASE2

Conditions

Malignant Peritoneal Mesothelioma, Advanced

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Cancer Institute and Hospital,Chinese Academy of Medical Sciences, Beijing, China
Contact: Study coordinator (Yongkun Sun) · hsunyk@cicams.ac.cn · 13141276041

Study leads

Yongkun Sun, Doctor
Study Chair
Cancer Institute and Hospital, Chinese Academy of Medical SciencesCancer

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

NSCLC Adenocarcinoma · Gastroesophageal Cancer (GC) · Gastric Adenocarcinoma

Abroad (travel likely)RecruitingPHASE1

Santa Rosa, United States · Washington D.C., United States

CT-95 in Advanced Cancers Associated With Mesothelin Expression

Mesothelin-Expressing Tumors · Epithelial Ovarian Cancer · Malignant Pleural Mesothelioma, Advanced

Abroad (travel likely)RecruitingPHASE1

Denver, United States · Chicago, United States